Funding of drugs: do vaccines warrant a different approach?
- 1 November 2008
- journal article
- review article
- Published by Elsevier BV in The Lancet Infectious Diseases
- Vol. 8 (11), 727-733
- https://doi.org/10.1016/s1473-3099(08)70258-5
Abstract
No abstract availableKeywords
This publication has 62 references indexed in Scilit:
- Optimal allocation of pandemic influenza vaccine depends on age, risk and timingVaccine, 2008
- Improving uptake of MMR vaccineBMJ, 2008
- The Global Burden of Disease Assessments—WHO Is Responsible?PLoS Neglected Tropical Diseases, 2007
- Precautionary Behavior in Response to Perceived Threat of Pandemic InfluenzaEmerging Infectious Diseases, 2007
- Influenza vaccine effectiveness in healthy 6- to 21-month-old children during the 2003-2004 seasonThe Journal of Pediatrics, 2006
- Who Benefits from New Medical Technologies? Estimates of Consumer and Producer Surpluses for HIV/AIDS DrugsForum for Health Economics and Policy, 2006
- A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older AdultsThe New England Journal of Medicine, 2005
- The Role of Economic Evaluation in Vaccine Decision MakingPharmacoEconomics, 2005
- Valuing Prevention Through Economic EvaluationPharmacoEconomics, 2004
- Economic Evaluations of Varicella Vaccination ProgrammesPharmacoEconomics, 2003